Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For VTAMA® (tapinarof) with Enhanced Therapeutic and Market Extension Prospects
Conduit Pharmaceuticals (Nasdaq: CDT) has filed two groundbreaking patents for VTAMA® (tapinarof), including a dual active cocrystal formulation that combines the drug with a complementary substance to address both therapeutic needs and side effects in inflammatory skin conditions.
The new patents come as VTAMA® approaches its 2027 exclusivity expiration. The innovation aims to enhance patient benefits by addressing symptoms like pain and itch, while extending patent protection and expanding therapeutic applications. This development is particularly significant as tapinarof enters clinical trials for cutaneous lupus and shows promise in other inflammatory and autoimmune indications.
The strategic timing aligns with the growing anti-inflammatory therapeutics market, projected to exceed $233.6 billion by 2032. The company is actively seeking partnerships to leverage this breakthrough IP while continuing to advance its broader pipeline.
Conduit Pharmaceuticals (Nasdaq: CDT) ha depositato due brevetti innovativi per VTAMA® (tapinarof), inclusa una formulazione a cocrystal con doppio principio attivo che combina il farmaco con una sostanza complementare per affrontare sia le esigenze terapeutiche che gli effetti collaterali nelle condizioni infiammatorie della pelle.
I nuovi brevetti arrivano mentre VTAMA® si avvicina alla sua scadenza di esclusività nel 2027. L'innovazione mira a migliorare i benefici per i pazienti affrontando sintomi come dolore e prurito, estendendo al contempo la protezione brevettuale e ampliando le applicazioni terapeutiche. Questo sviluppo è particolarmente significativo poiché il tapinarof entra in fase di sperimentazione clinica per il lupus cutaneo e mostra promesse in altre indicazioni infiammatorie e autoimmuni.
Il tempismo strategico si allinea con il crescente mercato dei farmaci anti-infiammatori, previsto per superare i 233,6 miliardi di dollari entro il 2032. L'azienda sta attivamente cercando partnership per sfruttare questa proprietà intellettuale innovativa, continuando a far progredire il suo ampio portafoglio.
Conduit Pharmaceuticals (Nasdaq: CDT) ha presentado dos patentes innovadoras para VTAMA® (tapinarof), incluyendo una formulación de cocrystal de doble acción que combina el fármaco con una sustancia complementaria para abordar tanto las necesidades terapéuticas como los efectos secundarios en condiciones inflamatorias de la piel.
Las nuevas patentes llegan a medida que VTAMA® se acerca a su vencimiento de exclusividad en 2027. La innovación tiene como objetivo mejorar los beneficios para los pacientes al abordar síntomas como el dolor y el picor, al tiempo que extiende la protección de la patente y amplía las aplicaciones terapéuticas. Este desarrollo es particularmente significativo ya que el tapinarof entra en ensayos clínicos para el lupus cutáneo y muestra promesas en otras indicaciones inflamatorias y autoinmunitarias.
El momento estratégico se alinea con el creciente mercado de terapias antiinflamatorias, que se proyecta que superará los 233,6 mil millones de dólares para 2032. La empresa está buscando activamente asociaciones para aprovechar esta propiedad intelectual innovadora mientras continúa avanzando en su amplia cartera.
콘듀잇 제약 (Nasdaq: CDT)는 VTAMA® (타피나로프)에 대한 두 가지 혁신적인 특허를 출원했습니다. 이 특허에는 약물과 보완 물질을 결합하여 염증성 피부 질환에서 치료 요구와 부작용을 모두 해결하는 이중 활성 공동 결정체 제형이 포함됩니다.
새로운 특허는 VTAMA®가 2027년 독점권 만료에 가까워짐에 따라 등장했습니다. 이 혁신은 통증과 가려움증과 같은 증상을 해결하여 환자의 이점을 향상시키고, 특허 보호를 연장하며, 치료 응용을 확장하는 것을 목표로 합니다. 이 개발은 타피나로프가 피부 루푸스에 대한 임상 시험에 들어가고 다른 염증 및 자가 면역 질환에서도 가능성을 보이는 만큼 특히 중요합니다.
전략적 타이밍은 2032년까지 2336억 달러를 초과할 것으로 예상되는 성장하는 항염증 치료 시장과 일치합니다. 이 회사는 이 혁신적인 지식 재산을 활용하기 위해 파트너십을 적극적으로 모색하고 있으며, 폭넓은 파이프라인을 지속적으로 발전시키고 있습니다.
Conduit Pharmaceuticals (Nasdaq: CDT) a déposé deux brevets révolutionnaires pour VTAMA® (tapinarof), y compris une formulation à cocrystal à double action qui combine le médicament avec une substance complémentaire pour répondre à la fois aux besoins thérapeutiques et aux effets secondaires dans les conditions cutanées inflammatoires.
Les nouveaux brevets arrivent alors que VTAMA® approche de son expiration d'exclusivité en 2027. L'innovation vise à améliorer les bénéfices pour les patients en s'attaquant à des symptômes tels que la douleur et les démangeaisons, tout en prolongeant la protection par brevet et en élargissant les applications thérapeutiques. Ce développement est particulièrement significatif alors que le tapinarof entre dans des essais cliniques pour le lupus cutané et montre des promesses dans d'autres indications inflammatoires et auto-immunes.
Le timing stratégique s'aligne avec le marché croissant des thérapies anti-inflammatoires, qui devrait dépasser 233,6 milliards de dollars d'ici 2032. L'entreprise recherche activement des partenariats pour tirer parti de cette propriété intellectuelle révolutionnaire tout en continuant à faire progresser son large portefeuille.
Conduit Pharmaceuticals (Nasdaq: CDT) hat zwei bahnbrechende Patente für VTAMA® (Tapinarof) eingereicht, darunter eine duale aktive Cocrystal-Formulierung, die das Medikament mit einer ergänzenden Substanz kombiniert, um sowohl therapeutische Bedürfnisse als auch Nebenwirkungen bei entzündlichen Hauterkrankungen zu adressieren.
Die neuen Patente kommen, während VTAMA® sich seiner Exklusivitätsablauf im Jahr 2027 nähert. Die Innovation zielt darauf ab, die Vorteile für die Patienten zu verbessern, indem Symptome wie Schmerzen und Juckreiz angegangen werden, während der Patentschutz verlängert und therapeutische Anwendungen erweitert werden. Diese Entwicklung ist besonders bedeutend, da Tapinarof in klinische Studien für kutanen Lupus eintritt und auch in anderen entzündlichen und autoimmunen Indikationen vielversprechend ist.
Das strategische Timing passt zum wachsenden Markt für entzündungshemmende Therapeutika, der voraussichtlich 233,6 Milliarden Dollar bis 2032 überschreiten wird. Das Unternehmen sucht aktiv nach Partnerschaften, um dieses bahnbrechende geistige Eigentum zu nutzen und gleichzeitig sein breiteres Portfolio weiterzuentwickeln.
- Filed strategic patents that could extend market exclusivity beyond 2027
- Novel cocrystal formulation addresses both therapeutic needs and side effects
- Potential expansion into broader inflammatory/autoimmune market
- Targeting $233.6B market opportunity by 2032
- Current VTAMA formulation faces patent expiration and generic competition by 2027
- New formulation still requires clinical validation and regulatory approval
- Success depends on securing strategic partnerships
Insights
Conduit's filing of novel cocrystal patents for tapinarof represents a significant strategic move in pharmaceutical lifecycle management. With VTAMA® facing patent expiration in 2027, this timing is particularly shrewd. The dual active cocrystal approach isn't merely a reformulation but creates a new composition of matter by pairing tapinarof with complementary agents addressing both disease pathology and symptom management.
This strategy creates three distinct value drivers: potential clinical superiority by targeting symptoms like pain and itch that current formulations neglect, extended market exclusivity beyond the 2027 cliff, and expanded therapeutic applications into the broader
The intellectual property strategy is particularly noteworthy as it comes at a crucial inflection point when tapinarof is expanding beyond dermatology into cutaneous lupus and other autoimmune indications. By filing now, Conduit establishes IP protection covering these emerging applications just as clinical evidence is being generated.
The reference to Organon's
Conduit's cocrystal patent filing demonstrates sophisticated business strategy by addressing the impending 2027 patent cliff for VTAMA®. Rather than simply extending formulation patents (which offer weaker protection), they've created potentially novel composition of matter IP by developing dual-active cocrystals.
The market potential is compelling across two dimensions. First, the established dermatology applications where VTAMA® is already approved (psoriasis and atopic dermatitis), addressing known tolerability issues that limit current market penetration. Second, expansion into the broader inflammatory and autoimmune markets represents exponential growth potential.
This IP strategy perfectly aligns with Conduit's business model of enhancing clinically validated assets for partnership rather than building commercial infrastructure. By focusing development on patient-centric improvements (addressing pain and itch alongside disease pathology), they've created differentiation that could command premium pricing even after generic entry of the original formulation.
The timing of this announcement – while tapinarof enters trials for cutaneous lupus – creates advantageous partnership leverage. Potential licensees now face a choice between securing rights to the improved, patent-protected formulation or risking competition from a potentially superior product just as they begin establishing the broader market applications.
This strategic move significantly enhances Conduit's partnership negotiating position by addressing the key barrier to long-term value creation for VTAMA®.
- Conduit Pharmaceuticals files next generation cocrystal patent for VTAMA® (tapinarof) which the Company believes could be a superior asset with both inflammatory and autoimmune prospectives just as the drug approaches 2027 exclusivity expiration, positioning the Company for high-value licensing partnerships.
NAPLES, Fla. and CAMBRIDGE, United Kingdom, April 11, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit" or the “Company”) today announces the filing of two groundbreaking patents for tapinarof (VTAMA®), including a dual active cocrystal, pairing the drug currently approved in the US for psoriasis and atopic dermatitis with a complementary drug substance known to address key patient needs in inflammatory skin conditions. The Company anticipates this combination drug approach could offer enhanced patient benefits over existing tapinarof formulations by addressing both therapeutic needs and known side effects, such as pain and itch, which are a known priority to sufferers of these conditions but typically overlooked by standard treatments that focus on the underlying disease alone.
This innovative approach differentiates Conduit's intellectual property from existing formulation patents, offering potential partners a next generation tapinarof asset with what the Company estimates to be extensive commercial viability. This comes at a critical juncture for VTAMA®, a drug that has demonstrated blockbuster potential through Organon's
Conduit believes this new IP could enable formulations of tapinarof that address three key market needs: improved patient tolerability, extended patent protection, and expanded therapeutic applications. The global market for anti-inflammatory therapies, projected to exceed
The addition of this new asset to Conduit's portfolio reinforces the Company's business model of identifying and enhancing clinically validated compounds with high commercial potential. This approach previously yielded success with Conduit's development of AZD1656 for autoimmune diseases and continues to drive the Company's pipeline strategy. With the anti-inflammatory therapeutics market as a whole growing at nearly
"With this strategic addition to our portfolio, we are not just adding another asset, but adding what we believe to be a highly commercially valuable patent position for tapinarof," said Dr. Joanne Holland, Chief Scientific Officer of Conduit Pharmaceuticals. "Whilst the current formulation is focused purely on underlying disease, our tapinarof cocrystal aims to offer a multifaceted approach addressing patient symptoms as well as disease. New composition of matter IP, on a drug that could imminently face generic competition on near-term exclusivity expiry, could offer partners a strong position to exploit its market potential in the wider inflammatory and autoimmune space. We are now actively pursuing partnerships that can leverage this breakthrough IP while we continue to advance our broader pipeline."
About Conduit Pharmaceuticals
Conduit is a multi-asset clinical stage, life science company delivering an efficient model for compound development. Conduit both acquires and funds the development of Phase 2-ready assets, building an integrated and advanced platform-driven approach powered by artificial intelligence (AI) and cybernetics, and seeking an exit through third-party license deals following successful clinical trials. Led by a highly experienced team of pharmaceutical executives including Dr. David Tapolczay and Dr. Freda Lewis-Hall, this novel approach is a departure from the traditional pharma/biotech business model of taking assets through regulatory approval.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release, including statements regarding Conduit's future results of operations and financial position, Conduit's business strategy, prospective product candidates, product approvals, research and development costs, timing and likelihood of success, plans and objectives of management for future operations, future results of current and anticipated studies and business endeavours with third parties, and future results of current and anticipated product candidates, are forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to; the inability to maintain the listing of Conduit's securities on Nasdaq; the ability to recognize the anticipated benefits of the business combination completed in September 2023, which may be affected by, among other things, competition; the ability of the combined company to grow and manage growth economically and hire and retain key employees; the risks that Conduit's product candidates in development fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable authorities on a timely basis or at all; changes in applicable laws or regulations; the possibility that Conduit may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties to be identified in the proxy statement/prospectus (as amended and supplemented) relating to the business combination completed in September 2023, including those under "Risk Factors" therein, and in other filings made by Conduit with the U.S. Securities and Exchange Commission. Moreover, Conduit operates in a very competitive and rapidly changing environment. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond Conduit's control, you should not rely on these forward-looking statements as predictions of future events. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, Conduit assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Conduit gives no assurance that it will achieve its expectations.
Investors & Media:
info@conduitpharma.com
FAQ
What is the significance of CDT's new patent filing for VTAMA?
How large is the market opportunity for CDT's enhanced VTAMA formulation?
What new indications is VTAMA (CDT) being developed for?
When does VTAMA's current market exclusivity expire for CDT?
